![]() |
Market Research Report
Product code
1036283
Metabolomics: Technologies and Global Markets |
Metabolomics: Technologies and Global Markets |
Published: November 5, 2021
BCC Research
Content info: 157 Pages
Delivery time: 1-2 business days
|
The global metabolomics market should reach $22.7 billion by 2026 from $12.7 billion in 2021 at a compound annual growth rate (CAGR) of 12.3% for the forecast period of 2021 to 2026.
The separation techniques segment of the global metabolomics market is expected to grow from $5.1 billion in 2021 to $8.7 billion in 2026 at a CAGR of 11.3% for the forecast period of 2021 to 2026.
The detection techniques segment of the global metabolomics market is expected to grow from $4.0 billion in 2021 to $7.1 billion in 2026 at a CAGR of 12.4% for the forecast period of 2021 to 2026.
This report examines the current and forecasted market potential for metabolomics. It offers a detailed analysis of the market background, technological advancement, competitive environment, drivers and restraints, and market growth trends. This report includes market projections through 2026, detailing the market share for metabolomics based on product, indication and application type.
By product, the metabolomics market is segmented into separation techniques, detection techniques, assays, and bioinformatics. By indication type, the metabolomics market is segmented into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. The others segment covers respiratory diseases, infectious diseases, etc. By application, the metabolomics market is segmented into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, and others.
By geography, the metabolomics market has been segmented into Europe, North America, Asia-Pacific (APAC), Latin America, and the Middle East & Africa (MEA). The detailed analyses of major countries such as the U.S., Germany, Canada, the U.K., Spain, Italy, France, Japan, India, and China are found in the regional segments. For market estimates, data is provided for 2020 as the base year, for 2021 and forecast through year-end 2026. Estimated values used are based on metabolomics companies' total revenues. Projected and forecast revenue values are in constant U.S. dollars that have not been adjusted for inflation.